Hend Andrew, MD
Family Medicine · New Port Richey, FLNPI 1366456881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 332 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,661, 2.3 times the $725 reported in 2019. Among family medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$746
- Novo Nordisk$733
- Pfizer$452
- GSK$437
- Amgen$417
- Lilly USA, LLC$409
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,672100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $746 |
| Novo Nordisk | 45 | $733 |
| Pfizer | 23 | $452 |
| GSK | 26 | $437 |
| Amgen | 24 | $417 |
| Lilly USA, LLC | 25 | $409 |
| Boehringer Ingelheim | 18 | $308 |
| Kowa Pharmaceuticals America, Inc. | 23 | $305 |
| Amarin Pharma, Inc. | 13 | $201 |
| Johnson & Johnson | 10 | $187 |
| AbbVie | 8 | $159 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $155 |
| Exact Sciences | 8 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Teva Pharmaceuticals USA, Inc. | 4 | $84 |
| Sumitomo Pharma America, Inc. | 5 | $82 |
| Merck | 6 | $80 |
| Vertex | 2 | $65 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Phadia US Inc. | 3 | $58 |
| Bayer | 3 | $58 |
| Abbott | 3 | $57 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Eisai Inc. | 3 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $43 |
| Novartis | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Astellas Pharma US Inc | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Bioventus LLC | 1 | $19 |
| Si-bone, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $15 |
How this compares
$5,672 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 46 | $41,846 |
| JardianceEmpagliflozin | 24 | $38,186 |
| MounjaroTirzepatide | 32 | $36,208 |
| EliquisApixaban | 28 | $34,901 |
| OzempicSemaglutide | 29 | $34,585 |
| JanuviaSitagliptin Phosphate | 35 | $31,814 |
| XareltoRivaroxaban | 13 | $22,391 |
| MyrbetriqMirabegron | 18 | $19,537 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,963 |
| SynthroidLevothyroxine Sodium | 34 | $3,929 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $3,183 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $2,427 |
| Rosuvastatin Calcium | 170 | $2,402 |
| Levothyroxine Sodium | 169 | $1,953 |
| Atorvastatin Calcium | 207 | $1,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $746 | $41,84646 claims |
| Boehringer IngelheimJardiance | $308 | $38,18624 claims |
| Lilly USA, LLCMounjaro | $409 | $36,20832 claims |
| PfizerEliquis | $452 | $34,90128 claims |
| Novo NordiskOzempic | $733 | $34,58529 claims |
| MerckJanuvia | $80 | $31,81435 claims |
| Johnson & JohnsonXarelto | $187 | $22,39113 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $19,53718 claims |
| GSKAnoro Ellipta | $437 | $7,96313 claims |
| AbbVieSynthroid | $159 | $3,92934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in New Port Richey
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.